Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (11-20 of 858) with videos related to

Pageof 86
Sort By:
The American Journal of Medicine|May 30, 2002
Oral glycoprotein IIb/IIIa inhibition--great idea, but it didn't workChristopher P Cannon
The American Journal of Geriatric Cardiology|July 31, 2003
Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapiesChristopher P Cannon
JAMA|November 18, 2011
High-density lipoprotein cholesterol as the Holy GrailChristopher P Cannon
The American Journal of Cardiology|March 12, 2021
Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial FibrillationChristopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndromeChristopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMIChristopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
Critical Pathways in Cardiology: a journal of evidence-based medicine: translating evidence into practiceChristopher P Cannon
Clinical Cornerstone|February 14, 2006
The endocannabinoid system: a new approach to control cardiovascular diseaseChristopher P Cannon
Journal of the American College of Cardiology|August 27, 2013
Should we measure quality by the dose?Christopher P Cannon
European Heart Journal|August 22, 2020
Chronic kidney disease: a high-risk group that deserves intensive lipid loweringChristopher P Cannon
Pageof 86

Showing results (11-20 of 858) with videos related to

Sort By:
Pageof 86
The American Journal of Medicine|May 30, 2002
Oral glycoprotein IIb/IIIa inhibition--great idea, but it didn't workChristopher P Cannon
The American Journal of Geriatric Cardiology|July 31, 2003
Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapiesChristopher P Cannon
JAMA|November 18, 2011
High-density lipoprotein cholesterol as the Holy GrailChristopher P Cannon
The American Journal of Cardiology|March 12, 2021
Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial FibrillationChristopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndromeChristopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMIChristopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
Critical Pathways in Cardiology: a journal of evidence-based medicine: translating evidence into practiceChristopher P Cannon
Clinical Cornerstone|February 14, 2006
The endocannabinoid system: a new approach to control cardiovascular diseaseChristopher P Cannon
Journal of the American College of Cardiology|August 27, 2013
Should we measure quality by the dose?Christopher P Cannon
European Heart Journal|August 22, 2020
Chronic kidney disease: a high-risk group that deserves intensive lipid loweringChristopher P Cannon
Pageof 86